Cargando…
The future of the development of medicines in idiopathic pulmonary fibrosis
The development of treatments for idiopathic pulmonary fibrosis (IPF) has been often disappointing. Building on authorized treatments that can benchmark the validity of treatment effect measures, the time has come to standardize endpoints and achieve consensus on their use for different clinical que...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4581513/ https://www.ncbi.nlm.nih.gov/pubmed/26399608 http://dx.doi.org/10.1186/s12916-015-0480-7 |